Characterization of patients with dystrophic epidermolysis bullosa for collagen VII therapy

British Journal of Dermatology

Volumn 173, Issue 3, 2015, Pages 821-823

  Gorell, E S ^a   Nguyen, N ^a   Siprashvili, Z ^a   Marinkovich, M P ^a,b   Lane, A T ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VA PALO ALTO HEALTH CARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGEN TYPE 7; COLLAGEN TYPE 7 A; UNCLASSIFIED DRUG; COL7A1 PROTEIN, HUMAN;

AMINO TERMINAL SEQUENCE; ANTIBODY DETECTION; ANTIBODY PRODUCTION; ANTIGEN ANTIBODY COMPLEX; CARBOXY TERMINAL SEQUENCE; COMPLEMENT DEPOSITION; CROSS REACTION; DERMOEPIDERMAL JUNCTION; ENZYME LINKED IMMUNOSORBENT ASSAY; EPIDERMOLYSIS BULLOSA DYSTROPHICA; EXON; GENETIC SCREENING; HUMAN; IMMUNE RESPONSE; IMMUNOFLUORESCENCE; LETTER; LOSS OF FUNCTION MUTATION; PRIORITY JOURNAL; SKIN BIOPSY; SUBSTITUTION THERAPY; WESTERN BLOTTING; GENETICS; MUTATION; PATIENT SELECTION;

COLLAGEN TYPE VII; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPIDERMOLYSIS BULLOSA DYSTROPHICA; HUMANS; MUTATION; PATIENT SELECTION;

EID: 84942364058     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/bjd.13737     Document Type: Letter

References (10)

1. Fine JD, Bruckner-Tuderman L, Eady RA, et al., Inherited epidermolysis bullosa: updated recommendations on diagnosis and classification. J Am Acad Dermatol 2014; 70: 1103-26.
2. Ortiz-Urda S, Garcia J, Green CL, et al., Type VII collagen is required for Ras-driven human epidermal tumorigenesis. Science 2005; 307: 1773-6.
3. Gupta R, Woodley DT, Chen M,. Epidermolysis bullosa acquisita. Clin Dermatol 2012; 30: 60-9.
4. Hovnanian A, Rochat A, Bodemer C, et al., Characterization of 18 new mutations in COL7A1 in recessive dystrophic epidermolysis bullosa provides evidence for distinct molecular mechanisms underlying defective anchoring fibril formation. Am J Hum Genet 1997; 61: 599-610.
5. Tanaka T, Takahashi K, Furukawa F, Imamura S,. The epitope for anti-type VII collagen monoclonal antibody (LH7:2) locates at the central region of the N-terminal non-collagenous domain of type VII collagen. Br J Dermatol 1994; 131: 472-6.
6. Kiritsi D, Garcia M, Brander R, et al., Mechanisms of natural gene therapy in dystrophic epidermolysis bullosa. J Invest Dermatol 2014; 134: 2097-104.
7. Woodley DT, Cogan J, Wang X, et al., De novo anti-type VII collagen antibodies in patients with recessive dystrophic epidermolysis bullosa. J Invest Dermatol 2014; 134: 1138-40.
8. Tampoia M, Bonamonte D, Filoni A, et al., Prevalence of specific anti-skin autoantibodies in a cohort of patients with inherited epidermolysis bullosa. Orphanet J Rare Dis 2013; 8: 132.
9. Pendaries V, Gasc G, Titeux M, et al., Immune reactivity to type VII collagen: implications for gene therapy of recessive dystrophic epidermolysis bullosa. Gene Ther 2010; 17: 930-7.
10. Falabella AF, Valencia IC, Eaglstein WH, Schachner LA,. Tissue-engineered skin (Apligraf) in the healing of patients with epidermolysis bullosa wounds. Arch Dermatol 2000; 136: 1225-30.